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Background: Patients with acutely decompensated cirrhosis (AD) may or may not
develop acute-on-chronic liver failure (ACLF). ACLF is characterized by high-grade
systemic inflammation, organ failures (OF) and high short-term mortality. Although
patients with AD cirrhosis exhibit distinct clinical phenotypes at baseline, they have low
short-term mortality, unless ACLF develops during follow-up. Because little is known
about the association of profile of systemic inflammation with clinical phenotypes of
patients with AD cirrhosis, we aimed to investigate a battery of markers of systemic
inflammation in these patients.
Methods: Upon hospital admission baseline plasma levels of 15 markers (cytokines,
chemokines, and oxidized albumin) were measured in 40 healthy controls, 39
compensated cirrhosis, 342 AD cirrhosis, and 161 ACLF. According to EASL-CLIF
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criteria, AD cirrhosis was divided into three distinct clinical phenotypes (AD-1:
Creatinine<1.5, no HE, no OF; AD-2: creatinine 1.5–2, and or HE grade I/II, no OF;
AD-3: Creatinine<1.5, no HE, non-renal OF).
Results: Most markers were slightly abnormal in compensated cirrhosis, but markedly
increased in AD. Patients with ACLF exhibited the largest number of abnormal markers,
indicating “full-blown” systemic inflammation (all markers). AD-patients exhibited distinct
systemic inflammation profiles across three different clinical phenotypes. In each
phenotype, activation of systemic inflammation was only partial (30% of the markers).
Mortality related to each clinical AD-phenotype was significantly lower than mortality
associated with ACLF (p < 0.0001 by gray test). Among AD-patients baseline systemic
inflammation (especially IL-8, IL-6, IL-1ra, HNA2 independently associated) was more
intense in those who had poor 28-day outcomes (ACLF, death) than those who did not
experience these outcomes.
Conclusions: Although AD-patients exhibit distinct profiles of systemic inflammation
depending on their clinical phenotypes, all these patients have only partial activation
of systemic inflammation. However, those with the most extended baseline systemic
inflammation had the highest the risk of ACLF development and death.
Keywords: acute decompensation, cirrhosis, signature, ACLF, organ failure, organ dysfunction
INTRODUCTION
Natural history of patients with acutely decompensated (AD)
cirrhosis may be complicated by acute-on-chronic liver failure
(ACLF) (1). ACLF, which has been intensively investigated
during the recent years, is characterized by the presence of
organ failure(s) (OFs) and high short-term mortality (1–4). The
diagnosis of OFs is based on the CLIF-COF scoring systemwhich
assesses the deterioration in the function of the six major organ
systems, including liver, kidney, coagulation, brain, circulation,
and respiration (1). ACLF is recognized when patients have either
a single renal failure; moderate renal dysfunction (creatinine
between 1.5 and 1.9 mg/dl) and/or cerebral dysfunction (grade I
and II hepatic encephalopathy) in combination with any isolated
non-renal OF; or twoOFs ormore (1). ACLF is also characterized
by the presence of high-grade systemic inflammation. Many
biomarkers of systemic inflammation are elevated in ACLF, and
associated with outcome (5–12).
Abbreviations: ACLF, acute-on-chronic liver failure; AD, acute decompensation;
ADH, antidiuretic hormone; ALT, alanine aminotransferase; BUN, blood urea
nitrogen; BT, bacterial translocation; CHE, cholinesterase; G-CSF, granulocyte-
colony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating
factor; HE, hepatic encephalopathy; HNA2, human non-mercaptalbumin-2; HRS,
hepatorenal syndrome; HPLC, high performance liquid chromatography; IL,
interleukin; IL-1ra, IL-1 receptor antagonist; INFγ, interferon gamma; INR,
international normalized ratio; IP-10 (CXCL10), 10kDa interferon gamma-
induced protein (C-X-C-motif chemokine 10); MCP-1 (CCL2), monocyte
chemotactic protein 1 (C-C-motif chemokine 2); MELD, model for end-stage liver
disease; MIP-1β, macrophage inflammatory protein 1-beta; NASH, non-alcoholic
steatohepatitis; PBC, primary biliary cirrhosis; SD, standard deviation; SEM,
standard error of the mean; SI, systemic inflammation; TNFα, tumor necrosis
factor alpha.
Unlike patients with ACLF, patients with AD have low
short-term mortality (1). AD-patients without ACLF at hospital
admission may present three distinct clinical phenotypes which
do no overlap (1). The first phenotype (hereafter called
AD-1) includes patients without any single OF, who have
serum creatinine of <1.5 mg/dL and do not have hepatic
encephalopathy (HE). The second phenotype (AD-2) includes
patients with isolated renal dysfunction and/or HE I or II,
but without any associated single non-renal OF. Finally, the
third phenotype (AD-3) includes patients with a single non-
renal OF without any kidney dysfunction. Although it is known
that some AD-patients without ACLF at hospital admission
can subsequently develop ACLF and die (1), the baseline
profile of systemic inflammation in these patients developing
or not ACLF during short-term follow-up is unknown. Also
the profiles of systemic inflammation across the three distinct
clinical phenotypes have not been investigated. Expanding our
knowledge about the profile of systemic inflammation associated
with each clinical phenotype should deliver not only insights
into the pathogenesis of ACLF, and also provide clinical tools for
stratification of patients and therapy (e.g., anti-TNF, G-CSF).
We hypothesized that each of the three distinct clinical
phenotypes which compose the group of patients with AD
cirrhosis who were free of ACLF may have a distinctive baseline
inflammatory profile. In addition, we wondered whether, among
the patients with AD cirrhosis without ACLF, the baseline
inflammatory profile was able to distinguish those who will
develop ACLF during follow-up from who will not, as well as
differentiate those who will die from those who will remain alive.
To address these hypotheses, we investigated a battery of markers
of systemic inflammation in a large cohort of 582 individuals
including healthy controls, patients with compensated cirrhosis
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without prior decompensation, patients with AD who were free
of ACLF, and patients with ACLF.
PATIENTS AND METHODS
Patients
In all patients, presence of cirrhosis was diagnosed either by
unequivocal signs in imaging, presence of complications of
portal hypertension or development of AD and/or ACLF. This
study analyzed a total of 582 individuals, of whom 542 were
patients with cirrhosis. Three hundred and forty-two of these
had been enrolled in the CANONIC study and were selected
because they had AD cirrhosis but no ACLF at enrollment
(1). These 342 patients were compared to 39 patients with
compensated cirrhosis who had never presented an episode of
decompensation, and 40 healthy volunteers as negative controls.
Moreover, 161 patients with ACLF (95 ACLF grade 1, 66 patients
with ACLF grade 2) enrolled in the CANONIC study were
selected to serve as positive controls, since those patients have
an extensive elevation of all systemic inflammation markers.
The selection of the CANONIC study patients was based on
the availability of blood samples within the first 2 days after
enrollment from patients under intensive surveillance during
hospitalization (5). All patients gave their written informed
consent. Each center obtained the ethics approval from the local
ethics committee for the CANONIC study (1, 5).
Definition of AD Cirrhosis, OF, and ACLF
AD of cirrhosis was defined according to criteria established by
the CANONIC study (1). Briefly, it includes acute development
of large ascites, hepatic encephalopathy, gastrointestinal
hemorrhage, bacterial infection, or any combination of these (1).
Individual OFs were diagnosed according to the CLIF-C OF
score (1). Liver failure was defined by serum bilirubin of 12 mg/dl
or more, kidney failure by creatinine of 2 mg/dl or more (or renal
replacement therapy), coagulation failure by INR of 2.5 or more.
Circulatory failure was diagnosed when vasopressors were used,
and respiratory failure when the patient received mechanical
ventilation (not due to HE-induced coma) or PaO2/FiO2 was 200
or lower. Finally, cerebral failure was defined as HE grade III and
IV (1).
As mentioned earlier, three distinct phenotypes characterized
of patients with AD without ACLF at admission, and ACLF
was defined according to criteria established by the CANONIC
study (1).
Data Collection
Healthy controls were recruited among 45–65 year-old medical
and non-medical staff from the Hospital Clinic, while patients
with compensated cirrhosis were recruited from the University
Hospital Bologna, University Hospital Padova and Royal Free
Hospital London and the data at baseline were recorded.
Data from the CANONIC study patients were obtained as
previously described (1, 5). Briefly, data from previous medical
history, physical examination, and laboratory parameters were
recorded at baseline, including etiology, previous episodes of
acute decompensation, potential precipitating events and reason
for hospitalization. Moreover, close 28-day follow-up data were
collected according to the CANONIC protocol (1). Finally,
information on liver transplantation, mortality and causes of
death were obtained on day 28, and at 3 and 6 months and 1 year
after enrollment.
Sample Collection and Analysis
of biomarkers
The baseline blood samples were obtained in Vacutainer EDTA
tubes at the time of enrollment in the study and/or within the first
2 days after enrolment in the study (48 h of hospital admission).
Samples at the last assessment could be obtained in 132 patients.
In all cases, blood was rapidly centrifuged at 4◦C and the plasma
frozen at−80◦C until analysis.
We measured TNF-α, IL-6, IL-8, MCP-1, IP-10, MIP-1β, G-
CSF, GM-CSF, IL-10, IL-1ra, INFγ, IL-17A, IL-7, and eotaxin in
25 µl of plasma using a multiplexed bead-based immunoassay
(Milliplex MAP Human Cytokine/Chemokine Magnetic Bead
Panel (Merck Millipore, Darmstadt, Germany) on a Luminex
100 Bioanalyzer (Luminex Corp., Austin, TX). The readouts
were analyzed with the standard version of the Milliplex Analyst
software (Merck Millipore). A five-parameter logistic regression
model was used to create standard curves (pg/mL) and to
calculate the concentration of each sample. Finally, the levels
of irreversibly oxidized albumin (HNA2) were assessed by high
performance liquid chromatography (5) as marker of systemic
oxidative stress. The levels of systemic inflammation markers in
patients with ACLF have been published previously (5).
Statistical Analysis
Plasma levels were above detection limits in most patients.
In healthy subjects and patients with values of cytokines
or any other measurement below the detection limit, the
threshold of detection was assigned as the determined value.
Results are presented as frequencies and percentages for
categorical variables, means and SDs for normally distributed
continuous variables and medians with interquartile range
for not normally distributed continuous variables. Hierarchical
clustering analysis was performed using the GP plot package
from R software. Intensity of inflammation was evaluated
according to the relationship between the set of cytokines
in different combinations stratifying for different groups of
patients. In univariate statistical comparisons, Chi-square test
was used for categorical variables, Student’s t-test or ANOVA
for normal continuous variables and Mann-Whitney U-test
or Kruskal-Wallis test for non-normal continuous variables.
Multiple-testing was corrected by the Bonferroni correction
(corrected p-value for 15 markers 0.05/15 = 0.003). To assess
the strength of the association between each marker and ACLF,
logistic regression models were performed. Factors showing a
clinically and statistically significant association to the outcome
in univariate analyses were selected for the initial model. The
final models were fitted using a stepwise forward method based
on likelihood ratios with the same significance level (p < 0.05)
for entering and dropping variables. The proportional hazards
model for competing risks proposed by Fine and Gray was used
to identify independent predictors of mortality as previously
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described (1). This model was chosen to account for liver
transplantation as an event “competing” withmortality. Variables
with a skewed distribution were log-transformed for statistical
analyses and graphical comparisons. A p- ≤ 0.05 was considered
statistically significant. Analyses were done with SPSS V. 23.0,
SAS V.9.4, and R V.3.4.2 statistical packages.
RESULTS
General Characteristics of the Patients
This study investigated 15 markers of systemic inflammation
and oxidative stress in 342 AD-patients but without ACLF
at admission. These were compared to the levels measured
in 161 patients admitted to the hospital with ACLF grade
1 or 2, 39 patients with compensated cirrhosis and no
prior decompensation episode, and 40 healthy controls
(Supplementary Tables 1,2). The reason for selecting only
patients with ACLF grade 1 or 2 was to exclude severely diseased
patients who had three OFs or more, since the enormous
elevation of inflammatory markers in these patients may make
difficult the comparison of their profile of systemic inflammation
with that of patients with AD and without ACLF.
Importantly, our patients with compensated cirrhosis had
never experienced any decompensation, despite the fact that
these patients were at risk of developing it. Briefly, these patients
had a mean value of 37.8 kPa (21.4–49.7 kPa) measured by
Fibroscan R© (Echosense, France) and median platelet count of
108 x 109/L (72–159× 109/L), surrogates suggesting the presence
of clinical significant portal hypertension (13). Moreover, in
18 (46%) patients, esophageal varices were already diagnosed.
Of note, levels of systemic inflammation markers were only
moderately altered in patients with compensated cirrhosis
compared to healthy controls (Supplementary Table 1),
indicating the absence of significant systemic inflammation
in most of these patients. Of note, patients with compensated
cirrhosis were analyzed only in a cross-sectional manner,
precluding any assessment of the development of AD disease in
these patients (Supplementary Table 1).
While the demography was similar, there were
important, but expected between-group differences, with
the most abnormal values being observed in the ACLF
group (Supplementary Table 2).
Markers of Systemic Inflammation
According to the Three Clinical
Phenotypes in AD Patients
The profile of systemic inflammation markers significantly
differed across the three phenotypes of AD without ACLF (AD-
1, AD-2, and AD-3; Figure 1, Table 1 depicting median values).
Interestingly, lower levels of TNF-α (OR, 0.52; 95%-CI, 0.34–
0.79), eotaxin (OR, 0.57; 95% CI, 0.38–0.86) and HNA2 (OR,
FIGURE 1 | Heat-map highlighting medians of the levels of the different biomarkers of systemic inflammation in patients with acutely decompensated (AD) cirrhosis
(with and without ACLF). The patients with “ACLF-free” AD cirrhosis were stratified into three phenotypes. The first phenotype (AD-1) included patients without any
single OF, who have serum creatinine of <1.5 mg/dL and do not have hepatic encephalopathy. The second phenotype (AD-2) included patients with isolated renal
dysfunction and/or cerebral dysfunction, i.e., without any associated single non-renal, non-cerebral OF. The third phenotype (AD-3) included patients with a single
non-renal OF, without any kidney dysfunction. The magnitude of the levels is color-coded and the clustering for each marker with the rest of the markers is shown to
the left of the heat-map.
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0.64; 95% CI, 0.45–0.91) were independently associated with AD-
1, while higher levels of TNF-α (OR, 3.25; 95% CI, 2.00–5.28) and
HNA2 (OR, 1.75; 95%CI, 1.20–2.55) but lower levels of IL-8 (OR,
0.67; 95% CI, 0.53–0.85) were independently associated with AD-
2 (renal and/or cerebral dysfunction, Supplementary Table 3).
FIGURE 2 | Cumulative incidence function assessing survival in patients’
groups analyzed in Figure 1. Mortality was significantly higher in patients with
ACLF than in those without, irrespective of their phenotype, AD-1, AD-2, or
AD-3 (Gray’s test p < 0.0001). Mortality did not significantly differ between the
three phenotypes AD-1, AD-2, and AD-3. For definitions of these phenotypes,
see Figure 1 legend.
By contrast, higher levels of IL-8 (OR, 2.30; 95% CI, 1.72–
3.06) and lower levels of G-CSF (OR, 0.78; 95% CI, 0.64–0.94)
were independently associated with isolated non-renal OF (AD-
3, Supplementary Table 3). Importantly, all these results were
independent of presence of infection, since we could not find
any association of those markers with the presence of infection
in the respective stratification of the patients, while IL-6 was
independently associated with infection in the entire cohort (OR,
1.36; 95%-CI 1.13–1.65; p= 0.01).
Interestingly, the pattern of elevated markers for patients
in AD-2 and AD-3 were opposite to each other, i.e., markers
that were elevated in AD-2 were lower in AD-3 and vice-versa
(Figure 1). The addition of elevated markers in AD-2 with the
elevated markers in AD-3, recapitulated the profile of systemic
inflammation seen in ACLF (Figure 1).
Importantly, not only the distribution of elevated biomarkers,
but also the quantitative changes in their levels defined their
affiliation to either AD-1, AD-2, or AD-3 (Figure 1, Table 1).
Another interesting finding was that patients with ACLF did not
show the highest levels of the single markers, but the highest
number of elevatedmarkers (Figure 1), suggesting a “full-blown”
systemic inflammation in this group of patients and a rather
attenuated systemic inflammation in the groups of patients
without ACLF.
Another important observation was that despite the
significant differences between the severity and profile of
systemic inflammation markers across the three clinical
phenotypes of “ACLF-free” AD cirrhosis, the cumulative
incidence of death by 90 days, was similar irrespective
FIGURE 3 | Heat-map showing the median levels of systemic inflammation markers at enrollment of patients with acutely decompensated cirrhosis who were free of
ACLF. For the comparison, patients were divided into two groups according to their outcome (i.e., development of ACLF or not, during 28 days of follow-up). The
magnitude of the levels is color-coded and the clustering for each marker with the rest of the markers is shown to the left of the heat-map.
Frontiers in Immunology | www.frontiersin.org 6 March 2019 | Volume 10 | Article 476
Trebicka et al. Inflammatory Signatures in Acute Decompensation
of the phenotype (Figure 2). In contrast, the “full-blown”
systemic inflammation observed in patients with ACLF was
associated with increased cumulative incidence of death by 90
days (Figure 2).
Predicting ACLF Development Using
Baseline Systemic Inflammation Profiles
Next, we asked whether among AD-patients without ACLF at
admission, the baseline systemic inflammation profile differed
between those who will subsequently develop ACLF relative
to those who will not develop this syndrome. Among the 342
patients with AD at admission, 57 developed ACLF within 28
days after admission. Importantly, baseline levels of systemic
inflammation markers were significantly higher among patients
who subsequently developed ACLF than among those who
remained free of ACLF during the 28-day follow-up (Figure 3,
Table 2). Therefore, in AD-patients without ACLF at admission,
the development of ACLF can be predicted using the baseline
profile of systemic inflammation-related markers.
When observing the magnitude of specific markers among
patients with AD cirrhosis who were free of ACLF on admission,
we saw that higher baseline levels of IL-6 (OR, 1.43; 95% CI,
1.04–1.96; p = 0.03), IL-1ra (OR, 1.46; 95%-CI 1.10–1.93; p
= 0.009) and HNA2 (OR, 2.84; 95%-CI 1.52–5.34; p = 0.001)
were independently associated with development of ACLF within
28 days.
Baseline Profiles Predicting Survival in
Patients With “ACLF-free” AD cirrhosis
Among AD-patients without ACLF at hospital admission
55 died and 28 received a liver transplant. The baseline
levels of several markers were significantly higher in patients
who subsequently died than in those patients who survived
(Supplementary Table 4; Figure 4). In particular, TNF-α, IL-6,
IL-8, IL-10, eotaxin, IL-17A, IL-7, and HNA2 were higher in
patients who died (Supplementary Table 4). Nevertheless, only
IL-8 and HNA2 were independently associated with mortality in
the patients with AD at baseline (Table 3).
DISCUSSION
This study offers a homogeneous classification way in
the heterogeneous population of patients with acutely
decompensated cirrhosis, which is related to ACLF development
and death. Beyond the large sample size, our study provides
novel information by showing that each of the three distinct
clinical phenotypes, which compose the group of patients with
AD cirrhosis who were free of ACLF had a distinctive baseline
inflammatory profile. A second aspect of the novelty in our
results is that, among the patients with AD cirrhosis without
ACLF, the baseline inflammatory profile was able to distinguish
those who will develop ACLF during follow-up from who
will not. Finally, we showed that among the patients with AD
cirrhosis without ACLF, the baseline inflammatory profile was
different between those who will die at short-term and those who
will survive.
This novel point of view is demonstrated in four major
findings of the present study discussed in the following. The
first was that inflammatory markers were only slightly altered
in patients with compensated cirrhosis and no prior episode
of decompensation. This finding is surprising and interesting
considering that many of these patients had clinical significant
portal hypertension, as assessed either by the presence of
esophageal varices and/or high liver stiffness and low platelets
(15). By contrast, most inflammatory mediators were markedly
increased in patients admitted to hospital with AD (with
or without ACLF). Indeed, this observation is of importance
since it shows that severe systemic inflammation and acute
decompensation of cirrhosis are concomitant processes, as
proposed in the so-called “Systemic Inflammation Hypothesis”
(16). This novel finding is probably a result of the careful
review of the medical history of the patients included in
the compensated control group, excluding any patients with
compensated cirrhosis who had prior history of AD episodes.
Although it remains unclear which of these processes (acute
decompensation or severe systemic inflammation) occurs first,
it is tempting to assume that systemic inflammation is a
prerequisite for the development of AD cirrhosis. In any case, our
findings suggest that systemic inflammation may serve to classify
the stage of disease in patients with cirrhosis.
The second important observation was that patients with AD
but without ACLF at admission had a very heterogeneous profile
of circulating inflammatory mediators. There were three distinct
clinical phenotypes (AD-1, AD-2, and AD-3) characterizing
those AD patients; each phenotype being associated with
distinct profile of systemic inflammation, irrespective of the
fact that infection was present or not. The patients hospitalized
with AD cirrhosis and neither OF, renal dysfunction nor
cerebral dysfunction (AD-1 phenotype), had very mild systemic
inflammation, while the patients with an isolated non-renal OF
(AD-3 phenotype), and those with isolated renal and/or cerebral
dysfunction (AD-2 phenotype) had a higher number of markedly
increased markers of systemic inflammation. Moreover, our
results obtained in patients with “ACLF-free” AD cirrhosis,
suggest a potential explanation for the systemic inflammation
signature of ACLF, which can be seen as a result of continuum
of activation of systemic inflammation. Indeed, according to
the EASL-CLIF consortium definition, the combination of any
single non-renal, non-cerebral OF with renal and/or cerebral
dysfunction defines ACLF grade 1. While some markers of
inflammation were elevated in patients with AD-3 phenotype,
other markers were elevated in patients with AD-2 phenotype.
As suggested by Figure 1, the profile of systemic inflammation
in ACLF could be seen as merging of the inflammatory profile
of the AD-2 phenotype and that of the AD-3 phenotype. It
could be argued that the division of ACLF-free AD cirrhosis into
three phenotypes was arbitrary, one phenotype (AD-2) being
more severe than the two others. However, several features do
not support this contention. First, the rationale for dividing this
group of patients into three distinct phenotypes was based on
clinical evidence provided by the CANONIC study (1). Second,
the results of the present study now provide a biological support
to this distinction by showing that each clinical phenotype was
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FIGURE 4 | Heat-map showing the median levels of systemic inflammation markers at enrollment of patients with acutely decompensated cirrhosis who were free of
ACLF. For the comparison, patients were divided into two groups according to their outcome (i.e., occurrence of death or not during 90 days of follow-up). The
magnitude of the levels is color-coded and the clustering for each marker with the rest of the markers is shown to the left of the heat-map.
TABLE 3 | Hazard ratios for death at 90 days in univariate and multivariable analyses of inflammatory mediators assessed at enrolment of 342 patients with acutely
decompensated cirrhosis who were free of ACLF.
Inflammatory mediator Univariate analysis Multivariate analysis
Hazard ratio 95% IC P-value Hazard ratio 95% IC P-value
Tumor necrosis factor-α 1.650 (1.056–2.578) 0.028 – – –
Interleukin-6 1.389 (1.094–1.764) 0.007 – – –
Interleukin-8 1.521 (1.256–1.842) <0.001 1.608 (1.304–1.982) <0.001
Eotaxin 2.765 (1.392–5.492) 0.004 – – –
Interleukin-17A 1.217 (1.033–1.434) 0.019 – – –
Interleukin-7 1.221 (1.047–1.422) 0.011 – – –
Human non-mercaptalbumin 2 2.116 (1.456–3.074) <0.001 2.237 (1.506–3.323) <0.001
The final models were fitted using a stepwise forward method based on likelihood ratios with the same significance level (p < 0.05) for entering and dropping variables. IC denotes
confidence interval.
associated with a specific inflammatory profile. Third, none of
these inflammatory profiles was as intense as the profile found in
patients with ACLF. It was also interesting that, although marked
differences in systemic inflammation profiles existed between
the three clinical phenotypes of “ACLF-free” AD cirrhosis, there
were no significant differences in survival between these three
phenotypes. Together these findings indicate that the division
into 3 phenotypes was not arbitrary, and more importantly did
not underestimate the severity of one phenotype, in particular
of the AD-2 phenotype. Our data are novel and very important,
indicating that not a maximum level of a specific biomarker, but
rather the extension (number of elevated markers) of systemic
inflammation, such as that observed in ACLF, must be reached to
determine increased mortality. Yet further studies are required to
refine the risk assessment in these phenotypes.
There were, however, some differences in the pattern of
systemic inflammation across the three clinical phenotypes of
“ACLF-free” AD cirrhosis. For example, the presence of an
isolated renal and/or cerebral dysfunction was independently
associated with high TNF-α levels, while an isolated single non-
renal OF was associated with low TNF-α levels. The reasons for
these between-group differences in TNF-α expression are unclear
but may explain some interesting observations of prior studies.
Thus, large-scale trials in severe alcoholic hepatitis showed that
anti-TNF approaches (e.g., pentoxifylline) might not work in
patients with severe disease and liver failure, but had positive
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effects in the presence of renal failure (17, 18). Pentoxifylline has
also been shown to improve outcomes in patients with alcoholic
hepatitis and hepato-renal syndrome (19, 20).
In our study, some markers (i.e., TNF-alpha, HNA2, and IP-
10) were elevated in AD-2 patients and lower in AD-3 patients,
features, which could seem counterintuitive. We have no clear
explanation for these differences, which contribute to the fact
that each clinical phenotype has a specific inflammatory profile.
We can only speculate on the pathophysiological consequences
of differences in some marker levels. For example, TNF-alpha
is known to protect the liver by stimulating liver regeneration
(21). Therefore, increased TNF-alpha levels in AD-2 may be
involved in the absence of liver failure in this group, and,
conversely, low TNF-alpha levels could favor the development
of liver failure in AD-3 patients. Obviously, future studies are
needed. Surprisingly, TNF-alpha and MCP-1 levels were both
lower in patients with compensated cirrhosis than in healthy
subjects. We do not have clear explanations for these differences,
only hypotheses. As mentioned earlier, TNF-alpha is known to
stimulate liver regeneration. Therefore, low TNF-alpha levels in
patients with compensated cirrhosis may reflect an insufficient
TNF-alpha production in the liver, playing a role in subclinical
liver failure in these patients. Regarding MCP-1, one should have
in mind that this chemokine is produced by damaged tissues to
attract monocytes whose function, once migrated, is to restore
tissue homeostasis. Therefore, low MCP-1 levels in compensated
cirrhosis may result in defective tissue homeostasis.
A third highly relevant finding was the observation that
patients with AD cirrhosis who were free of ACLF at
enrollment but subsequently developed ACLF within 28
days, had significantly higher baseline levels of inflammatory
mediators. Moreover, these patients showed a distinct signature
of systemic inflammation, relative to those who did not
develop ACLF. These findings reveal that systemic inflammation
precedes the development of ACLF, suggesting a cause-to-
effect relationship. Importantly, in our study, higher IL-6 levels
independently predict ACLF development, a finding which is
consistent with previous results showing that elevated IL-6 levels
were strongly associated with ACLF and its progression (5).
Moreover, higher IL-1ra levels were independently associated
with development of ACLF, which is fully in line with previous
data demonstrating that polymorphisms of IL-1ra predispose
to ACLF (22). Finally, HNA2, a marker for oxidative stress,
was independently associated with ACLF development (5, 23).
This latter finding calls for an important discussion not only
on the pathogenesis of ACLF, but also on the prophylactic
treatment since albumin is a potent immune modulator involved
in reducing oxidative stress. In fact, there is strong evidence
that albumin administration during an episode of spontaneous
bacterial peritonitis prevents type I HRS—which represents
a special form of ACLF—and improves survival (24). This
has also recently been confirmed in the ANSWER trial, a
randomized controlled trial in almost 400 patients, showing
that long-term weekly albumin administration reduces the
incidence of organ failure and thereby improves overall survival
in decompensated cirrhotic patients (25). Further studies (e.g.,
PRECIOSA, NCT03451292) are underway.
Finally, in patients with “ACLF-free” AD cirrhosis, the
extension of systemic inflammation at baseline was associated
with 90-day mortality. The independent predictors of death were
higher levels of IL-8 and HNA2 suggesting that decreasing the
levels of these two inflammation-related markers may be an
objective for future therapies aiming to increase survival in the
group of patients with AD who are at high risk of death. Of note,
among patients with AD at enrollment, those who will die had
lower G-CSF levels than those who will survive. These patients
might benefit from G-CSF therapy as recently shown in patients
with ACLF (26).
Although the present study tested a large number of patients
and a large number of systemic inflammation mediators, it
has its limitations. The concept of this study is to observe
systemic inflammation associated with AD cirrhosis (with and
without ACLF) without taking into account specific events that
could have precipitated the acute decompensation of cirrhosis
(e.g., data about use of anti-inflammatory drugs, although
unlikely since contraindicated in these patients). Moreover,
there might be inter-center heterogeneity in the diagnosis of
portal hypertension, although each liver unit participating in the
CANONIC study had expertise in the diagnosis and treatment
of complications of cirrhosis, therefore limiting the inter-center
heterogeneity. Finally, this study did not aim to elaborate on a
specific score, but rather to offer pathophysiologic insight into the
role of systemic inflammation in patients with AD. Future studies
are needed to further elaborate the specific events in AD cirrhosis.
In conclusion, baseline inflammatory markers exhibit no
or slight abnormalities in compensated cirrhosis, while in
“ACLF-free” AD cirrhosis their profile was heterogeneous, being
markedly elevated in those who developed ACLF during follow
up.Moreover, among patients with AD cirrhosis who were free of
ACLF, this study showed a specific baseline profile of circulating
inflammatory mediators in patients who died during follow-up.
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